Intercept Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
August 03, 2022 07:00 ET
|
Intercept Pharmaceuticals, Inc.
Worldwide Ocaliva® non-GAAP adjusted net sales in PBC of $100.4 million; U.S. net sales of $71.8 million representing 5% growth over the prior year quarter Company reissues...
Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022
July 27, 2022 08:00 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)
July 07, 2022 07:30 ET
|
Intercept Pharmaceuticals, Inc.
OCA 25 mg met the agreed primary endpoint of improvement in liver fibrosis without worsening of NASH at 18 months (p<0.0001), consistent with the original REGENERATE analysis OCA 25...
Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S.
July 01, 2022 16:01 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Announces PBC Data Presentations at The International Liver Congress™ 2022
June 21, 2022 07:30 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Provides Update on NASH Regulatory Timeline
June 06, 2022 06:30 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Announces New Clinical Trial and Real-World Outcomes Data for Ocaliva in PBC
June 03, 2022 07:30 ET
|
Intercept Pharmaceuticals, Inc.
COBALT study in advanced PBC, previously terminated early due to feasibility challenges, did not demonstrate a statistically significant difference in clinical endpoints between Ocaliva® and placebo ...
Intercept Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis
May 11, 2022 08:00 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
May 06, 2022 07:00 ET
|
Intercept Pharmaceuticals, Inc.
Worldwide Ocaliva® net sales of $88.6 million, representing 8% growth over the prior year quarter Nearing completion of new REGENERATE data analyses; planning for potential pre-submission meeting...
Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, including $405MM Upfront and an Additional $45MM in Contingent Payments
May 05, 2022 07:17 ET
|
Intercept Pharmaceuticals, Inc.
Agreement includes rights for Advanz to commercialize orphan drug Ocaliva® for PBC outside the U.S., as well as the transition to Advanz of the international commercial and medical infrastructure of...